Neuroprotect

Neuro-Protect is a French clinical-stage biotechnology company dedicated to developing neuroprotective therapies for ophthalmic and neurological disorders. The company's primary focus is on preventing the degeneration of retinal ganglion cells, the key pathological event leading to irreversible vision loss in glaucoma. Its lead candidate, NP-612, is a proprietary formulation of the small molecule diltiazem, repurposed to provide direct neuroprotection to the optic nerve by blocking voltage-gated calcium channels. Unlike traditional glaucoma treatments that focus solely on lowering intraocular pressure, Neuro-Protect's approach aims to directly enhance neuronal survival. The company is also exploring its neuroprotective compounds for other indications, including various forms of optic neuropathy and retinal neurodegeneration.